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Therapies that are safe, effective, and not vulnerable to developing resistance are highly desirable to counteract bacterial infec-
tions. Host-directed therapeutics is an antimicrobial approach alternative to conventional antibiotics based on perturbing host
pathways subverted by pathogens during their life cycle by using host-directed drugs. In this study, we identified and evaluated
the efficacy of a panel of host-directed drugs against respiratory infection by nontypeable Haemophilus influenzae (NTHi).
NTHi is an opportunistic pathogen that is an important cause of exacerbation of chronic obstructive pulmonary disease
(COPD).We screened for host genes differentially expressed upon infection by the clinical isolate NTHi375 by analyzing cell
whole-genome expression profiling and identified a repertoire of host target candidates that were pharmacologically modulated.
Based on the proposed relationship between NTHi intracellular location and persistence, we hypothesized that drugs perturbing
host pathways used by NTHi to enter epithelial cells could have antimicrobial potential against NTHi infection. Interfering
drugs were tested for their effects on bacterial and cellular viability, on NTHi-epithelial cell interplay, and onmouse pulmonary
infection. Glucocorticoids and statins lacked in vitro and/or in vivo efficacy. Conversely, the sirtuin-1 activator resveratrol
showed a bactericidal effect against NTHi, and the PDE4 inhibitor rolipram showed therapeutic efficacy by lowering NTHi375
counts intracellularly and in the lungs of infected mice. PDE4 inhibition is currently prescribed in COPD, and resveratrol is an
attractive geroprotector for COPD treatment. Together, these results expand our knowledge of NTHi-triggered host subversion
and frame the antimicrobial potential of rolipram and resveratrol against NTHi respiratory infection.
Strategies formanaging infectious diseases havemainly focusedon targeting enzymes of pathogens, with antibiotics being the
most notable example of this approach. However, among the se-
rious disadvantages of this pathogen-directed strategy are the de-
velopment of microbial drug resistance (1) and the difficulty in
treating intracellular pathogens (2). Despite the growing need for
new antimicrobials, the rates of discovery for novel antibiotics are
declining (3). Therefore, new broad-spectrum therapeutics that
are safe, effective, and not vulnerable to the development of bac-
terial resistance are needed (4).
Pathogens exploit and subvert various host cell factors for sur-
vival and growth in an otherwise hostile environment. An alter-
native antimicrobial approach is to perturb host cell pathways
used by bacteria at various stages of their life cycle (adhesion,
entry, growth, etc.). This strategy, termed host-directed therapeu-
tics, promotes the use of host-directed antimicrobial drugs (5).
Identification of host targets requires a detailed understanding of
host-pathogen interactions. In the present study, we used global
expression profiling to elucidate cellular pathways exploited by
nontypeable Haemophilus influenzae (NTHi) to infect airway ep-
ithelia and evaluated drugs that, by perturbing these host cell tar-
gets, may limit infection by this opportunistic pathogen.
Although typically a commensal of the nasopharynx, the
Gram-negative bacteriumH. influenzae, especially in its unencap-
sulated or nontypeable form, is also an opportunistic pathogen
causing middle-ear infections, conjunctivitis, community-ac-
quired pneumonia, exacerbations of chronic obstructive pulmo-
nary disease (COPD), and occasionally, invasive disease (6).
Infections frequently persist and recur despite the host’s develop-
ment of bactericidal antibodies and the use of antibiotics. Our
current understanding of the molecular mechanisms involved in
NTHi infection remains limited, but identical strains have been
repeatedly isolated from the lungs ofCOPDpatients in serial clinic
visits, suggesting that NTHi presents features that promote
chronic infection (7, 8). NTHi is a facultative intracellular patho-
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gen (9–16), and epithelial invasion may allow bacterial cells to
temporarily evade the immune system and/or therapeutic inter-
ventions. Indeed, a correlation between the occurrence of intra-
cellularNTHi and persistent infection has been proposed (17, 18).
Based on these observations, a comprehensive understanding of
host factors hijacked byNTHi to invade airways epitheliamay lead
to the identification of targets for host-directed drugs with anti-
microbial potential.
NTHi infection is also an inflammatory process (19). Chronic
respiratory patients are prescribed anti-inflammatory therapies,
which may influence NTHi infection. In fact, glucocorticoids
modify NTHi gene expression (20), suppress host inflammation
via the upregulation of IRAK-M, enhance NTHi-induced Toll-
like receptor 2 (TLR2), and inhibit NTHi-induced MUC5A ex-
pression via mitogen-activated protein kinase (MAPK) phospha-
tase MKP-1-dependent inhibition of p38 MAPK (21–24).
Moreover, although glucocorticoids attenuate NTHi-triggered
inflammation in vivo, they also compromise bacterial clearance
(25). The 2 receptor agonist salmeterol seems to protect the re-
spiratory epithelium against H. influenzae-induced damage, but
inhalation of this bronchodilator may negatively influence NTHi
clearance from the murine airways (26, 27). The phosphodies-
terase 4 (PDE4) inhibitor roflumilast dampens NTHi-triggered
inflammation in the lung and middle ear by upregulation of the
deubiquitinase CYLD (28), but itmay also synergize withNTHi to
upregulate PDE4B2 expression via a cross talk between PKA-C
and p65, therefore contributing to chemokine induction (29).
Altogether, the proposed relationship between NTHi intracel-
lular location and persistence, as well as the observed modulation
of the NTHi-host cell interplay by anti-inflammatory therapies,
prompted us to hypothesize that drugs perturbing host pathways
used by NTHi to enter airway cells could have antimicrobial po-
tential against this pathogen. Based on this notion, we screened for
host cell pathways affected upon infection by a NTHi clinical iso-
late by analyzing whole-genome expression profiling in order to
identify potential host target candidates that can be inhibited by
commercially available drugs, including some U.S. Food and
Drug Administration (FDA)-approved compounds. Such inhibi-
torswere tested for their bactericidal effect, host cell toxicity, effect
on NTHi-host cell interplay, and effect on NTHi respiratory in-
fection in vivo. By focusing on drugs that were not cytotoxic, that
impair NTHi invasion of epithelial cells, and that lower bacterial
counts in vivo, we identified the PDE4 inhibitor rolipram as a
nonbactericidal host-directed drug able to dampen NTHi epithe-
lial invasion and to enhance mice lung clearance. Moreover, our
analysis revealed a bactericidal effect for the sirtuin-1 activator
resveratrol (RESV) against NTHi. We present here evidence for
the antimicrobial potential of rolipram and resveratrol against
NTHi respiratory infection.
MATERIALS AND METHODS
Bacterial strains, media, and growth conditions. NTHi strains were
grown at 37°C and 5% CO2 on chocolate-agar (bioMérieux) or on brain
heart infusion (BHI) agar supplemented with 10 g of hemin/ml and 10
g of NAD/ml, referred to here as sBHI. NTHi liquid cultures were grown
in sBHI. NTHi375 is a genome-sequenced clinical isolate previously used
in host-pathogen interplay studies (13, 14, 30).
Interfering drugs and molecules. Caffeic acid phenethyl ester
(CAPE), BAY11-7083, SB202190, SP600125, dexamethasone (DEX), flu-
ticasone propionate (FP), human epidermal growth factor (EGF), res-
veratrol (RESV), theophylline (TEOPH), TAPI-2 acetate salt, salmeterol
(SALM), formoterol fumarate dehydrate (FORM), (S)-()-propranolol
hydrochloride (PROP), N6,2=-O-dibutyryladenosine 3=,5=-cyclic mono-
phosphate sodium salt (db-cAMP), and 3-isobutyl-1-methylxanthine
(IBMX) were purchased from Sigma-Aldrich. Ro31-8220, roflumilast 3-
(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluorome
thoxy)benzamide (ROFLUM), rolipram (R,S)-4-(3-(cyclopentyloxy)-4-
methoxyphenyl)pyrrolidin-2-one (ROLIP), and 8-(4-chlorophenylthio)-
2=-O-methyladenosine 3=,5=-cyclic monophosphate monosodium (8-
pCPT-2=-O-Me-cAMP) were purchased from Santa Cruz Biotechnology.
PD98059, GM6001, fluvastatin (FLUV), and protein kinase A (PKA) in-
hibitor 14-22 amide (PKI) were purchased from Calbiochem. Stock solu-
tions for CAPE (17.6 mM), BAY11-7083 (6 mM), SB202190 (15.1 mM),
SP600125 (22.7 mM), PD98059 (18.7 mM), FP (1 mM), RESV (20 mM),
GM6001 (10 mM), FORM (10 mM), IBMX (560 mM), and ROFLUM
(12.4mM)were prepared in dimethyl sulfoxide (DMSO). Stock solutions
for Ro31-8220 (1.8mM),DEX (1mM), TAPI-2 (4.8mM), FLUV (5mM),
PROP (2.6 mM), db-cAMP (50.8 mM), 8-pCPT-2=-O-Me-cAMP (2
mM), and PKI (0.4 mM) were prepared in distilled water. EGF (165 nM)
was dissolved in 10mMacetic acid, TEOPH (2.7mM)was dissolved in 0.1
M NaOH, SALM (0.2 mM) was dissolved in phosphate-buffered saline
(PBS), and ROLIP (18.2 mM) was dissolved in ethanol. Drugs were di-
luted to the required working concentrations in Earle’s balanced salt so-
lution (EBSS).
To test bacterial viability in the presence of the interfering agents, a
bacterial suspension recovered with 1 ml of PBS from a freshly grown
chocolate-agar plate, was adjusted to an optical density at 600 nm (OD600)
of 1 (109 CFU/ml), and 100 l of this suspension was incubated for 2 h
with the working concentration of each drug (or an equivalent volume of
vehicle solution used as a control [CON]) in 1ml of EBSS. Serial dilutions
were plated on sBHI agar. Volumes used for each vehicle solution did not
reduce bacterial viability (data not shown). The data are expressed as the
percentage of viability compared to CONbacteria, considered to be 100%
(see Fig. S1 in the supplementalmaterial). Viability assayswere carried out
in duplicate on at least two separate occasions (n 4).
Resveratrol susceptibility assay. A bacterial suspension recovered
with 1ml of PBS froma freshly grown chocolate-agar platewas adjusted to
an OD600 of 0.5 (5  10
8 CFU/ml). Resveratrol was serially diluted in
sBHI (225, 175, 112.5, 56.25, 28.125, 14, 7, 3.5, 1.75, and 0.88 g/ml).
Portions (80l) of each resveratrol dilutionwere transferred to individual
wells in 96-well microtiter plates (Iwaki); 20l of the previously prepared
bacterial suspension was added to each well, followed by incubation for 40
min at 37°C. In parallel, 20l of the bacterial suspension was added to 80l
of sBHI containing DMSO volumes identical to those used for each resvera-
trol dilution. Bacteria were serially diluted in PBS and plated on sBHI agar.
The results are expressed as a percentage of the colony count of bacteria not
exposed to resveratrol, considered to be 100%. Experiments were performed
in duplicate on at least four independent occasions (n 8).
Cell culture and bacterial infection. Carcinomic human alveolar
basal epithelial cells (A549, ATCCCCL-185) weremaintained and seeded
in 24-well tissue culture plates as described previously (14). Adhesion and
invasion assays were performed and processed as previously described
(13, 14). The results are expressed as CFU per well. When indicated, the
cells were pretreated in EBSS with the panel of interfering molecules as
follows: (i) 20minwith 20MTEOPH; (ii) 30minwith 1mMIBMX; (iii)
1 h with 52.8 M CAPE, 5 M BAY11-7083, 50 M SP600125, 200
M GM6001, 100 M TAPI-2, 50 to 200 M FLUV, 1 mM db-cAMP, 1
M ROFLUM, 10 M ROLIP, or 1 M PKI; (iv) 90 min with 50 M
PD98059; (v) 2 h with 1MRo31-8220, 30MSB202190, 1MDEX, 10
M FORM, or 100 M 8-pCPT-2=-O-Me-cAMP; (vi) 3 h with 20 M
PROP; (vii) 4 h with 1MFP or 20MRESV; and (viii) 16 h with 82.5 to
165 nM EGF or 1 M SALM.When necessary, A549 cells were incubated
at 33 or 41°C 24 h before and during NTHi infection. When no bacteri-
cidal effect was observed, drug exposure was maintained during bacteri-
um-cell contact.When a bactericidal effect was observed (see Fig. S1 in the
supplemental material), cells were pretreated as indicated above, and the
Euba et al.
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drugs were removed prior to infection. In all cases, the cytotoxicity on
A549 cells at each drug working concentration was tested by measuring
the release of lactate dehydrogenase with a CytoTox-96 nonradioactive
cytotoxicity assay (Promega) and by microscopy (data not shown). Ex-
periments were performed in triplicate on at least three independent oc-
casions (n 9).
Immunofluorescencemicroscopy.A549 cells were seeded on 13-mm
circular coverslips, infectionswere performed as described previously (13,
14), and infected cells were incubated in RPMI 1640 containing 10% fetal
calf serum (FCS), HEPES 10 mM, and gentamicin at 200 g/ml for 60
min. The cells were then washed, fixed, and stained as previously de-
scribed (13, 14). NTHi375 was stained with rabbit anti-NTHi serum di-
luted 1:600 (14). GM1 ganglioside was stained with Vibrio cholerae toxin
subunit B conjugated to Texas Red (Molecular Probes) at 5 g/ml. Don-
key anti-rabbit conjugated to Cy2 secondary antibody (Jackson) was di-
luted 1:100. Samples were analyzed with a Leica TCS SP5 confocal micro-
scope.
RNA extraction, microarray hybridization, and data analysis. Total
RNA was isolated using a NucleoSpin RNAII kit (Macherey-Nagel), in-
cluding an on-columnDNase treatment step. Total RNAquality was eval-
uated using RNA 6000 Nano LabChips (Agilent 2100 Bioanalyzer). All
samples had intact 18S and 28S rRNA bands with RNA integrity numbers
(RIN) between 9.3 and 9.7 and an RNA A260/A280 ratio of 2.1. For mi-
croarray hybridization, samples (n  4) were processed using manufac-
turer protocols and hybridized to the Agilent Human 1A Microarray V2
with a single labeling.Data normalizationwas performed by using a quan-
tile algorithm. After quality assessment, a filtering process was performed
to eliminate low-expression probes. Applying the criterion of an expres-
sion value64 in three samples for each experimental condition, 18,235
probes were selected for statistical analysis. R and Bioconductor (31) were
used for preprocessing and statistical analysis. LIMMA (LinearModels for
Microarray Data) (32) was used to find out the probes that showed sig-
nificant differential expression between experimental conditions. Genes
were selected as significant using a B statistic cutoff of B 1. Functional
enrichment analysis of Gene Ontology (GO) categories was carried out
using a standard hypergeometric test (33). The biological knowledge ex-
traction was complemented through the use of Ingenuity Pathway Anal-
ysis (Ingenuity Systems).
Real-timequantitativePCR (RT-qPCR). cDNAwas synthesized from
total RNA (1 g) using SuperScript II reverse transcriptase reagents (In-
vitrogen). PCR amplification was performed by using Thermo Scientific
Luminaris HiGreen qPCR master mix (Thermo Scientific). Fluorescence
data were analyzed with ABI 7900HT Prism sequence detector software
(Applied Biosystems). The primer pairs, designed with Primer-BLAST
software (NCBI), are shown in Table S1 in the supplemental material.
Relative mRNA levels of each gene were normalized by using GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) as an internal control. The
relative quantities of mRNAs were obtained by using the comparative
threshold cycle (CT)method. Data are expressed as the relative expression
on infected cells compared to uninfected cells (considered to be 1; see Fig.
S3 in the supplemental material). All measures were carried out in dupli-
cate and at least three times (n 6).
Transient transfections. A549 cells were seeded, transfected, and in-
fected as previously described (13). Two small interfering RNAs (siRNAs)
for each gene (a and b) and a scramble nonsilencing RNA were synthe-
sized by Qiagen (see Table S2 in the supplemental material). siRNA (40
nM) was used for transfection. The cells were infected at 48 h posttrans-
fection. RNA interference (RNAi) efficiency was assessed at the mRNA
level by RT-qPCR on cell extracts at 48 h posttransfection, as detailed
above. Validation of interference is expressed as the percentage of mRNA
expression on siRNA transfected compared to AS-CON-transfected cells,
which was considered to be 100% (see Fig. S4 in the supplemental mate-
rial). Knockdown and subsequent infection assays were carried out in
duplicate and on at least in three separate occasions (n 6).
Secretionof IL-8.A549 cells weremaintained, seeded, and infected for
2 h, as described previously (10, 34). Cells were washed three times with
PBS and incubated for 6 h in RPMI 1640medium containing 10%FCS, 10
mM HEPES, and gentamicin (100 g/ml). Supernatants were collected
from the wells, cell debris was removed by centrifugation, and samples
were frozen at80°C. Interleukin-8 (IL-8) levels in the supernatants were
measured by enzyme-linked immunosorbent assay (ELISA; Abnova,
catalog no. KA0115) with a sensitivity of 	2 pg/ml. When necessary,
cells were pretreated with each drug or with vehicle solution, which
was kept during infection, including the gentamicin incubation pe-
riod. For fluvastatin, the cells were treated in EBSS prior and during
infection; during the gentamicin incubation period, this drug was
added to RPMI 1640 with 10 mM HEPES and 100 g of gentamicin/
ml, in the absence or presence of FCS. In all cases, infections were
performed in duplicate on at least two separate occasions (n 4). The
results are expressed as IL-8 pg/ml.
NTHi mouse lung infection. A CD1 mouse model of NTHi respira-
tory infection was used as described previously (7, 10, 34, 35). NTHi375
was used for lung infection, and mice were randomly divided into the
following six groups (n 5): (i) control A (intraperitoneally [i.p.] admin-
istered vehicle solution), (ii) control B (oroesophageal gavage adminis-
tered vehicle solution), (iii) a group treated daily with dexamethasone 10
days before infection, (iv) a group treated daily with fluvastatin 10 days
before infection, (v) a group treated with fluvastatin 24, 12, and 1 h before
infection and 6 h postinfection (hpi), and (vi) a group treated with rolip-
ram24, 12, and 1 h prior to infection and 6 hpi.Dexamethasone treatment
was performed at a dose of 2.5mg/kg of bodyweight in 0.1ml ofwater and
administered i.p. (36); fluvastatin treatments were performed at doses of 1
or 30 mg/kg of body weight in 0.1 ml of water and administered i.p. (37).
Rolipram treatment was performed at a dose of 10 mg/kg of body weight
in 0.1 ml of PBS-ethanol (2:1) and administered by oroesophageal gavage
(Popper& Sons, Inc.) (38).NTHi intranasal infectionwas performed, and
the lungs were processed as previously described (7, 10, 34, 35) at 12 or 24
hpi. Each lung homogenate was serially 10-fold diluted in PBS, and 100l
of each dilution was spread in triplicate on sBHI-agar (detection limit,	10
CFU/lung). The results are expressed as means 
 the standard deviations
(SD) of individual log10 CFU/lung.
Statistical analysis. For gene expression, bacterial viability, cell infec-
tion, IL-8 secretion, and bacterial loads in lungs, themeans
 the SDwere
calculated, and statistical comparisons of means were performed using a
two-tailed Student t test. In all cases, a P value of 	0.05 was considered
statistically significant. Analyses were performed using the Prism soft-
ware, version 4, for PC statistical package (GraphPad Software).
Database accession number.Microarray data files were submitted to
GEO (Gene ExpressionOmnibus) database and are available under acces-
sion number GSE69134.
RESULTS
Gene expression profiling identifies host functions differen-
tially expressed inNTHi-infected A549 human type II pneumo-
cytes. To examine the human airway epithelial transcriptional
response to NTHi infection, we performed expression profiling of
A549 cells infected with the clinical isolate NTHi strain 375 (here,
NTHi375) (I) or in cells left uninfected (NI). The samples were
collected at 2 h postinfection. This infection conditionwas used to
mimic early stages of the infectious process, when the pathogen
may modulate the expression of host functions to favor its entry
into the cells. Transcriptomic analysis using microarrays revealed
402 probes corresponding to 352 genes differentially expressed
(B 1) inA549-infected cells compared to controlNI cells. A heat
map of highly induced or repressed genes (B  1 and logFC 
1.5), clustered genes in two groups: those that were upregulated
and those that were downregulated in infected cells (Fig. 1A).
Some of the most representative canonical pathways enriched
Host-Directed Therapeutics against NTHi Infection
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with a Fisher exact test (P	 0.05) using Ingenuity Pathways Anal-
ysis (IPA) software included inflammatory responses (i.e., IL-17,
IL-6, and IL-8) and cell signaling (i.e., glucocorticoid receptor,
protein kinase A [PKA], and phosphatidylinositol 3-kinase
[PI3K]/AKT signaling) (Fig. 1B). Moreover, 25-gene clustering
networks were created by the IPA software. The network with the
highest score, together with networks 13, 14, and 19 (data not
shown) were related to ubiquitin C (see Fig. S2A in the supple-
mental material). We also focused on interactive networks 3 and
21, where we found SIRT1, encoding the NAD-dependent
deacetylase sirtuin-1 (see Fig. S2B in the supplemental material),
and HMGCR, encoding the 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCR; see Fig. S2D in the supplemental material),
respectively. In agreement with the enriched canonical pathways,
we found several phosphodiesterases (PDEs) in interactive net-
work 8 (see Fig. S2C in the supplemental material). Supporting
the observed transcriptional changes, RT-qPCR showed signifi-
cantly enhanced expression for IL-8, AREG, CXCL-1, andDUSP1
genes in A549-infected cells versus control uninfected cells (see
Fig. S3 in the supplemental material).
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FIG 1 NTHi alters the human airways epithelial transcriptomic response. (A) Intensity heat map and clustering of differentially expressed genes (B 1, logFC 2)
during infection (normalized expression values are shown). A549 cells were either not infected (NI) or infected (I) withNTHi375 for 2 h. Each row represents one gene
that was either upregulated (red), downregulated (green), or not affected (black) under each of the conditions relative to uninfected cells. (B) Selection of enriched
functions associated with differentially expressed genes with a Fisher exact test P value threshold set at 0.01 (red line) determined using IPA software.
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Drug repurposing against NTHi respiratory infection. Ge-
nome expression profiling revealed drug targets within the NTHi
infection transcriptional signature whose pharmacological inter-
ference could impair NTHi cell invasion and, potentially, respira-
tory infection. For example, PI3K/AKT signaling showed differ-
ential expression (Fig. 1B), and its involvement inNTHi epithelial
invasion has been reported (13, 14). Moreover, based on the oc-
currence of genes that are differentially expressed in NTHi-in-
fected cells and that encode known drug targets, we observed sev-
eral repurposing opportunities for launched drugs which are not
currently used in anti-NTHi therapy. These genes included SIRT1
(a target of resveratrol), HMGCR (a target of statins), and PDE4B
(the major PDE isoform expressed in lung and a target of roflu-
milast N-oxide) (see Fig. S2 in the supplemental material). Our
analysis also suggested an antimicrobial potential for the pharma-
cological interference of glucocorticoid receptor signaling and in-
flammation (Fig. 1B). We selected a panel of host target candi-
dates and assessed the effect of their pharmacological interference
on NTHi respiratory infection.
Glucocorticoid receptor signaling and NTHi respiratory in-
fection. IPA-based analysis showed that the highest-rated func-
tion associated with relative expression of NTHi-infected/nonin-
fected cells was glucocorticoid receptor signaling (Fig. 1B).
Glucocorticoids enhance NTHi-induced TLR2 upregulation via
MKP1 phosphatase-dependent inhibition of p38 MAPK (21, 24).
MKP1 also seems to lead to reduced activation of the extracellular
signal-regulated kinase (ERK) MAPK (39). Genome profiling re-
vealed that the MKP1 encoding gene DUSP1 and p38 MAPK sig-
naling are overexpressed in NTHi-infected cells. To determine
whether DUSP1 and p38MAPKplay a role inNTHi cell infection,
bacterial invasion was tested in the presence or absence of
Ro31-8220 or SB202190 inhibitors, respectively, which reduced
NTHi375 epithelial invasion (Ro31-8220, P  0.01; SB202190,
P  0.05) (Fig. 2B). Cell pretreatment with the ERK inhibitor
PD98059 did not alter NTHi375 cell invasion (Fig. 2B). Given that
NTHi-induced activation of JNK2 kinase has been reported (28),
we also tested the effect of cell exposure to the JNK inhibitor
SP600125 and found a significant reduction of NTHi375 invasion
(P 	 0.005). None of these drugs was bactericidal (see Fig. S1 in
the supplemental material), or modified bacterial epithelial adhe-
sion (Fig. 2A). Despite these observations, cell treatment with two
clinically used glucocorticoids, dexamethasone and fluticasone
propionate (the dose range tested for both drugs was 0.01 to 1
M), reduced IL-8 secretion by NTHi-infected cells (DEX, P 	
0.0005; FP, P 	 0.0001) but did not modify NTHi epithelial ad-
hesion or invasion (Fig. 2C to E). We also assessed the effect of
dexamethasone administration in vivo by using a mouse model of
NTHi respiratory infection and a regimen consisting ofDEXgiven
in 2.5-mg/kg daily administrations for 10 days prior to infection.
At 24 hpi, the NTHi burden in the lungs of mice treated with
dexamethasone was similar to that found in the lungs of control A
(CON) untreated mice (Fig. 2F). These results showed that, al-
though glucocorticoids reduceNTHi-triggered IL-8 secretion and
although the inhibition of some glucocorticoid signaling elements
impairs NTHi375 cell invasion, glucocorticoids do not modulate
NTHi epithelial invasion. Neither do they display an NTHi clear-
ing effect in vivo.
Inflammation signaling and epithelial infection by NTHi.
IPA-based analysis also showed that high-rated functions associ-
ated with the relative expression of infected versus noninfected
(I/NI) cells included inflammation signaling pathways (Fig. 1B).
These observations agreed with previous reports showing that
NTHi infection is an inflammatory process to be induced in
a TRAF6/IKK/NF-B-dependent manner (19). To determine
whether NF-B plays a role in NTHi location upon epithelial in-
fection, we tested the effect of the NF-B inhibitors CAPE and
BAY11-7083 on bacterial cell invasion. Given that both inhibitors
were bactericidal for NTHi375 (see Fig. S1 in the supplemental
material), the cells were pretreated prior but not during infection.
CAPE (P 	 0.05), but not BAY11-7083, reduced NTHi375 cell
invasion (Fig. 3B). These inhibitors did not modify NTHi375 ep-
ithelial adhesion (Fig. 3A). BAY11-7083 is an irreversible inhibitor
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ticasone propionate (FP) (C) and then infected with NTHi375 to determine
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treatedwith Ro31-8220, SB202190, PD98059, or SP600125 (B) or withDEXor
FP (D) and then infected with NTHi375 to determine invasion compared to
control (CON) untreated cells. Themean numbers for NTHi375 invasion into
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determined at 24 hpi (log10 CFU/lung).
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of IKK and IB phosphorylation. Although CAPE inhibits
NF-B (40), it may have additional properties, such as inhibition
of PI3K/AKT signaling (41). AKT phosphorylation implication in
NTHi cell invasion (14) could explain the different results ob-
tained for CAPE and BAY11-7083.
Given that NTHi-triggered inflammation seems to be medi-
ated by TLR2-dependent and epidermal growth factor receptor
(EGFR)-dependent signaling (19, 42), we also sought to deter-
mine whether these molecules play a role in NTHi epithelial in-
fection. NTHi375 invasion of cells transfected with two siRNAs (a
and b) to TLR2 and two siRNAs (a and b) to EGFR (see Fig. S4 in
the supplemental material) was similar to that observed for cells
transfected with AllStars control siRNA (Fig. 3C). Similarly, exog-
enous addition of the natural EFGR ligand EGF did not modify
NTHi375 cell invasion (Fig. 3D). In summary, the interference of
a number of host elements known to be involved in NTHi-trig-
gered inflammation did not modify bacterial entry into airway
epithelial cells.
Histone/protein deacetylation and NTHi epithelial infec-
tion.Gene clustering network created by the IPA software showed
intermolecular connections for SIRT1, encoding the deacetylase
sirtuin-1 (see Fig. S2B in the supplemental material). SIRT1 is a
negative regulator of matrix metalloproteinase-9 (MMP9) (43)
and protects against emphysema (44). Given that COPD relates to
an inappropriate elevation ofMMP9 (45) and to lung reduction of
SIRT1 (43), the activation of SIRT1 could be an attractive thera-
peutic approach (46). To determine whether SIRT1 plays a role in
NTHi epithelial invasion, cells were transfected with two siRNAs
to SIRT1, a and b (see Fig. S4 in the supplemental material).
NTHi375 invasion into cells transfected with SIRT1 siRNAs was
similar to that observed for cells transfected with control AllStars
siRNA (Fig. 4A). Given that the observed SIRT1 relative expres-
sion of I/NI cells could negatively regulate MMPs, we hypothe-
sized that MMP blockage should not impair NTHi cell invasion.
This was the case when NTHi375 cell invasion was tested in the
presence of the MMP inhibitors GM6001 and TAPI-2 (Fig. 4B).
Similarly, these drugs did not modulate bacterial cell adhesion
(see Fig. S5A in the supplemental material).
Therapeutic activation of SIRT1 could synergize with NTHi
infection, whichmay have unknown consequences in the lungs of
the chronically infected patients. Based on this notion, we assessed
the effect of resveratrol, a plant polyphenol that activates SIRT1
(47), on NTHi infection. Of note, resveratrol is bactericidal
against some bacteria (48). We tested resveratrol microbicidal ac-
tivity against NTHi and found that it decreased NTHi375 viability
in a dose-dependent manner and that bacterial survival was less
than 50% at a resveratrol concentration of 175 g/ml (P 	
0.0001) (Fig. 4C). Differently, cell pretreatment with resveratrol
did not alter NTHi375 cell adhesion or invasion (Fig. 4D and see
Fig. S5B in the supplemental material). As observed for resvera-
trol, the nonbactericidal histone deacetylase inducer theophylline
(49) did not alter NTHi375 epithelial adhesion or invasion (Fig.
4D and see Fig. S5B in the supplemental material).
These results indicate that modulation of histone/protein
deacetylases did not interfere with NTHi entry into airways epi-
thelial cells. Importantly, resveratrol showed antimicrobial poten-
tial as a natural bactericidal against NTHi.
Effect of cholesterol modulation on NTHi respiratory infec-
tion.Gene clustering network created by the IPA software showed
intermolecular connections for HMGCR (see Fig. S2D in the sup-
plemental material), the rate-controlling enzyme of the meval-
onate pathway, which produces cholesterol and other isoprenoids
(50).We showed previously that cholesterol is a component of the
host membrane lipid rafts important for NTHi epithelial invasion
(14). Supporting this notion, a temperature increase that could
affect host plasma membrane fluidity (51), enhanced NTHi375
cell invasion (P 	 0.0001) without modifying adhesion (Fig. 5A
and B), and a recruitment of the glycosphingolipid GM1 ganglio-
side to the NTHi infection site could be observed (Fig. 5C). Im-
portantly, HMGCR is the therapeutic target of statins, which are
hypolipidemic drugs used to lower cholesterol in people at risk of
cardiovascular disease (52). Targeting cholesterol has also become
an attractive antimicrobial approach becausemany pathogens ex-
ploit cholesterol or lipid rafts to establish infection (53). We next
sought to determine whether targeting cholesterol by a statin
could modulate NTHi infection. Cell treatment with fluvastatin
reduced NTHi375 cell invasion in a dose-dependent manner
(FLUV, 200 M; P 	 0.05), without altering adhesion (Fig. 5D
and E). Statin effect was restored by cholesterol replenishment
with FCS (Fig. 5F). In the absence of FCS, fluvastatin also reduced
IL-8 secretion in NTHi375-infected cells (P 	 0.0001) (Fig. 5G).
We next determined the effect of fluvastatin in vivo by using amouse
model of NTHi pulmonary infection and two statin regimens con-
sistingof (i) FLUV(1mg/kg) administrationdaily for10daysprior to
infection and mouse sacrifice at 24 hpi and (ii) FLUV (30 mg/kg)
administration 24, 12, and1hprior to infection and6hpi andmouse
sacrifice at 12 hpi. In both cases, NTHi burden in the lungs of mice
treated with fluvastatin was similar to that found in the lungs of con-
trol A (CON) untreatedmice (Fig. 5H). In summary, fluvastatin ad-
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ministration reducedNTHi invasion and IL-8 secretion by epithelial
cells but did not enhance bacterial clearance in vivo.
Modulation of PKA signaling and respiratory infection by
NTHi. We reported previously that intracellular cyclic AMP
(cAMP) increase by activation of adenylate cyclases reduces NTHi
cell invasion (13). Intracellular cAMP formation is initiated by
stimulation of Gs-protein-coupled 7-transmembrane receptors,
such as the 2-adrenergic receptors (54), and its levels are tightly
controlled by PDEs (55). The downstream cAMP effectors are
PKA and the cAMP-regulated guanine nucleotide exchange fac-
tors Epac1 and Epac2 (54). The PKA signaling axis contains sev-
eral drug targets, including 2 adrenoreceptors and PDEs, tar-
geted by 2 agonists and PDE inhibitors, respectively (56, 57).
Given that our IPA analysis showed a high-rated function for PKA
signaling in NTHi375-infected cells (Fig. 1B) and that gene clus-
tering network 8 showed intermolecular connections for several
PDEs (see Fig. S2C in the supplemental material), we assessed the
effect of interfering PKA signaling on NTHi infection. First, we
tested the effect of the 2 agonists salmeterol and formoterol. Cell
treatment with formoterol, but not with salmeterol, reduced (P
0.0005) NTHi375 invasion (Fig. 6A). These 2 agonists did not
alter NTHi375 epithelial adhesion (see Fig. S5C in the supplemen-
tal material). Formoterol effect was restored by the adrenoceptor
blocker propranolol (P 	 0.005) (Fig. 6A). Second, intracellular
cAMP levels were increased by cell exposure to (i) db-cAMP, a
mimic of endogenous cAMP, (ii) IBMX, a nonselective PDE in-
hibitor, and (iii) rolipram and roflumilast, two PDE4 inhibitors.
Cell exposure to these agents reduced NTHi375 invasion (db-
cAMP, P 	 0.05; ROFLUM, P 	 0.05; ROLIP, P 	 0.005) (Fig.
6B). Third, we tested the effect of cAMP effector modulation. In
agreement with previous data obtained by using H-89 (13), cell
exposure to the PKA inhibitor PKI increased significantly (P 	
0.0001) NTHi375 invasion; conversely, the selective EPAC activa-
tor 8-pCPT-2=-O-Me-cAMP did not modify bacterial invasion
(Fig. 6C). None of these drugs altered NTHi epithelial adhesion
(see Fig. S5D in the supplemental material). We next determined
the effect of rolipram administration in vivo by using a mouse
model of NTHi lung infection and a regimen consisting of rolip-
ram (10 mg/kg) oral administration at 24, 12, and 1 h prior to
infection and 6hpi. At 12 hpi, bacterial burden in the lungs ofmice
treated with rolipram was lower (P	 0.05) than that found in the
lungs of control B untreated mice (Fig. 6D).
These results indicate that a therapeutic increase in intracellu-
lar cAMP through 2 agonists or PDE inhibitors reduced NTHi
cell invasion.Moreover, rolipram reduced lung bacterial counts in
vivo, supporting its potential as a host-directed therapy against
NTHi respiratory infection.
DISCUSSION
This study investigated the efficacy of host-directed antimicrobial
therapies against respiratory infection by NTHi. Our approach
relied on the identification of host cell pathways subverted by this
pathogen for intracellular invasion. Therapeutic modulation of
such pathogen-hijacked host functionsmay have an antimicrobial
effect and, ultimately, impair the progression of the infection. We
used cell genome profiling and unraveled a NTHi-triggered cell
transcriptional signature, which revealed a panel of host-directed
target candidates whose therapeutic potential was further ex-
plored by analyzing the effect of their interference by specific
drugs. Our work on cultured cells and murine model systems of
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NTHi infection narrowed the microarray-generated panel of host
target and drug candidates to resveratrol, a bactericidal natural
polyphenol which also activates sirtuin-1, and to the nonbacteri-
cidal inhibition of PDE4. We acknowledge that genome expres-
sion profiling was performed on one cultured cell line with one
NTHi clinical isolate, which may limit the results obtained. How-
ever, to our knowledge, this is the first study based on host-di-
rected therapeutics devoted to identify novel treatment opportu-
nities against NTHi and also the first report on the antimicrobial
potential of resveratrol and rolipram against NTHi respiratory
infection.
Given that epithelial invasion may allow NTHi to temporar-
ily evade the host immune system (17, 18), we took intracellu-
lar invasion as an assay to test the microarray-generated panel
of host target and drug candidates. This type of assay has been
used to perform a chemical screening of drugs blocking the
entry and/or the intracellular growth of Coxiella burnetii, Legio-
nella pneumophila, Brucella abortus, Rickettsia conorii, or Myco-
bacterium tuberculosis (58, 59). Of note, some of the drugs tested
here did not alter NTHi adhesion to and invasion of A549
epithelial cells or, if they were found to impair NTHi cell inva-
sion, they did not favor bacterial clearance in vivo. Our results
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highlight the advantages and limitations of genome expression
profiling, demonstrating that this screening method generates
an expression signature contributing to our global understand-
ing of host functions subverted by the pathogen and also that,
as a discovery method for host therapeutics, this approach
needs to be further sustained by experimental models.
Several inflammation-related genes and cell functions were
differentially expressed in NTHi-infected cells. This observation,
in agreement with previous studies (19), attracted our interest
because (i) persistent NTHi respiratory infection is linked to
COPD exacerbation and irreversible progression, (ii) inflamma-
tion is a hallmark of COPD, and (iii) COPD patients are
administered anti-inflammatory drugs. Moreover, glucocortico-
ids modulate NTHi-triggered inflammation signaling (21, 24).
Here, we observed that the inhibition of MKP1, p38 MAPK and
JNK, but not of ERK MAPK, NF-B, TLR2, or EGFR, reduced
NTHi invasion. Conversely, although dexamethasone and flutica-
sone propionate reduced the epithelial inflammatory response
elicited by NTHi, it neither affected NTHi invasion nor had a
beneficial effect on bacterial clearance from the lungs of infected
mice. Our results support a previous report showing that dexa-
methasone treatment on cigarette-smoke-exposed mice chal-
lengedwithNTHi compromised the clearance of the bacteria (25).
Treatment of respiratory patientswith inhaled glucocorticoids has
also been associated with an excess risk of pneumonia hospitaliza-
tion, followed by death (60). These evidences suggest that cortico-
steroids may facilitate infections despite their anti-inflammatory
efficacy.
Cardiovascular comorbidity generates a frequent use of statins in
COPD patients whose effect on preventing exacerbations in moder-
ate-to-severe patients is under debate (61, 62). Previous studies have
suggested the involvement of cholesterol-rich lipid rafts in NTHi in-
tracellular invasion (13, 14), and expression profiling network clus-
tering highlighted HMGCR in NTHi-infected cells. Here, we ob-
served that fluvastatin reducedNTHi invasion and the inflammatory
response elicitedbyNTHionepithelial cells.However, it didnothave
a beneficial effect on bacterial clearance from the lungs of infected
mice. These results highlight the need of usingmultiple experimental
models, especially in vivo model systems. We acknowledge that st-
atins are a group of cholesterol-lowering drugs with different prop-
erties, such as different antimicrobial effects (63).Here, we examined
fluvastatin administered i.p. to mice. Other statins, together with al-
ternative routesof administration in vivo,will be the subjectof further
studies.
Modulation of intracellular cAMP is another therapeutic ap-
proach used to treat COPD, achieved by using2 agonists andPDE4
inhibitors. Given that PKA signaling was differentially expressed in
NTHi-infected cells and considering previous reports on PDE4B
overexpression upon NTHi infection (28, 29), we used a panel of
drugs to interfere PKA signaling at different levels. A549 cells have
been shown to express -adrenoreceptors (64), and we used two 2
agonists that yielded different results in terms of NTHi intracellular
 A
C
FU
/w
el
l (
x1
03
)
0
4
 B
C
FU
/w
el
l (
x1
03
)
2
6
0
1
2
3
 C  D
4
CON ROLIP
0
2
4
6
Lo
g 1
0
c.
f.u
./l
un
g
0
1
2
3
4
5
C
FU
/w
el
l (
x1
03
)
CON SALM FORM
PROP RO
LIP
RO
FLU
M
IBM
X
db-
cAM
P
CO
N
CON 8-pCPT-2’
-O-Me-cAMP
PKI
*
* *
* *
*
*
+ + _
_
+ + 
FIG6 PDE inhibitors have therapeutic potential against respiratory infection byNTHi. Effect of2 agonists onNTHi375 infection of A549 type II pneumocytes.
Cells received various treatments—salmeterol (SALM), formoterol (FORM), or propranolol (PROP) (A), db-cAMP, IBMX, roflumilast (ROFLUM), or rolipram
(ROLIP) (B), or 8-pCPT-2=-O-Me-cAMP or PKI (C)—and bacterial invasion was assessed. The mean numbers for NTHi375 invasion into FORM-treated cells
were lower than those obtained for control (CON) untreated cells (P 0.0005). The FORM-mediated effect was restored by the addition of PROP (P	 0.005).
The mean numbers for NTHi375 invasion into db-cAMP-, ROFLUM-, and ROLIP-treated cells were lower than those obtained for CON cells (db-cAMP, P	
0.05; ROFLUM, P	 0.05; ROLIP, P	 0.01). The mean numbers for NTHi375 invasion into PKI-treated cells were higher than those obtained for CON cells
(P	 0.0001). (D) Effect of ROLIP on bacterial counts in lungs. Mice were infected intranasally with108 bacteria/mouse. ROLIP (10mg/kg) was administered
orally 24, 12, and 1 h prior to infection and at 6 hpi. Bacterial counts were determined at 12 hpi (log10 CFU/lung). The NTHi375 counts were significantly lower
in the lungs of mice treated with ROLIP than in those of control B (CON) untreated mice (P	 0.05).
Host-Directed Therapeutics against NTHi Infection
December 2015 Volume 59 Number 12 aac.asm.org 7589Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 26, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
invasion. The structure, affinity, efficacy, kinetics, and ability to ele-
vate intracellular cAMP vary for salmeterol and formoterol (57, 65),
which could explain the differences observed. We also assessed the
effect of increasing intracellular cAMPby inhibitingPDEs.Bothnon-
selective and PDE4 selective inhibition reduced NTHi epithelial in-
vasion and, importantly, in vivo treatment with rolipram showed a
bacterial clearing effect. Supporting the therapeutic use of targeting
PDE4, the ototopical postinoculation administration of roflumilast
seems to suppress NTHi-induced inflammation in vivo (28). Roflu-
milast is currently administered to COPD patients (66). Despite its
anti-inflammatory effect (28), it seems toalso synergizewithNTHi to
induce PDE4B, which may contribute to developing tolerance (29).
Future work will further analyze the effect of roflumilast on NTHi
respiratory infection.
Although we sought here to identify antimicrobial drugs tar-
geting host targets, we also observed a bactericidal effect for res-
veratrol against NTHi, an effect similar to that shown before for
other bacteria (48). Given that resveratrol is both bactericidal
against NTHi and an activator of sirtuin-1 and that it has been
proposed to have beneficial health effects due to its antioxidant
and anti-inflammatory properties (67), we speculate that resvera-
trol could be a useful therapy against respiratory NTHi infection
associated with COPD. Further studies will tackle the resveratrol
bactericidal effect andmechanisms on collections ofNTHi clinical
isolates of different pathological origins and its efficacy in vivo.
In sum, our genome expression profiling of host target candi-
dates for intervention against NTHi respiratory infection revealed
awhole range of therapeutic opportunities, and our further assess-
ment showed a therapeutic potential for resveratrol and rolipram.
Hostmodulation is likely to avoid selective pressure for the evolution
ofmicrobial resistance and to afford broad-spectrumprotection, but
it must not deleteriously affect helpful elements of the immune re-
sponse (68). This tight balance should be necessarily taken into con-
sideration by researchers and clinicians interested in exploring the
antimicrobial benefits of host-directed therapeutics.
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